In this retrospective study, we provided the initial picture of the comparison on different treatment patterns as trastuzumab plus chemotherapy with or without anti-PD-1-based immunotherapy in HER2 positive GC/GEJ adenocarcinoma from one single center. Here, ERBB2 is linked to gastric cancer.